newsfilter
← Latest News
GlobeNewswire·

Albireo Reports Q1 2022 Financial Results and Business Update

Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled, patient numbers above original target and on trac